Therefore, targeting the CD27/CD70 signaling pathway or CD70-expressing malignant cells using CAR-T-cell therapy or antibodies represents a promising strategy for therapeutic intervention to address T cell exhaustion and suppression in MCL.58 This evidence concerns the gene CD70 and mantle cell lymphoma.